ALS Drug Promise | Athira Pharma's ATH-1105 shows potential in ALS treatment, with positive preclinical data and Phase 1 results driving future clinical plans |
Financial Crossroads | Despite $37M cash reserves, Athira faces financial challenges. Market cap decline to $9.8M reflects investor caution amid strategic shifts |
Strategic Pivot | Explore Athira's strategic review process and pursuit of partnerships to accelerate ATH-1105 development and enhance shareholder value |
Market Sentiment | Analyst ratings hold at "Market Perform" without price targets, reflecting cautious optimism as Athira advances its focused ALS program |
Metrics to compare | LONA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLONAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.5x | −9.1x | −0.3x | |
PEG Ratio | −0.02 | −0.37 | 0.00 | |
Price/Book | 1.4x | 2.2x | 2.6x | |
Price / LTM Sales | - | 11.4x | 2.9x | |
Upside (Analyst Target) | 155.7% | 84.2% | 56.7% | |
Fair Value Upside | Unlock | 1.0% | 10.2% | Unlock |
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company’s lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer’s disease and Parkinson’s disease, which is in phase 2 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.